BMB18 clinical trial expands to dual site
Open PDF
| Stock | Biome Australia Ltd (BIO.ASX) |
|---|---|
| Release Time | 27 May 2026, 8:43 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Biome Australia Expands BMB18 Clinical Trial to Dual Site
Key Points
- Multi-centre clinical trial for BMB18 initiated in Australia and Greece
- Three-arm study evaluates two dosage levels of BMB18
- Athens site led by Professor George Moschonis
- Recruitment starts within previously disclosed timeline
Full Summary
Biome Australia Ltd. has expanded its BMB18 clinical trial to include a second site at Harokopio University of Athens, led by Professor George Moschonis. This multi-centre trial, which also includes La Trobe University in Melbourne, is a three-arm, double-blind, placebo-controlled study evaluating two dosage levels of BMB18 against a placebo. The trial will involve 240 participants over a six-week intervention period, followed by a two-week post-intervention follow-up. Recruitment has begun this week, in line with the previously disclosed Q4 FY26 timeline.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In